中文 | English



Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners




Linkedbio Report No.161

In this month summary, Lingmed recommends

  • GBI report- Year in Review 2017: MNCs' approvals windfall as CFDA drives systemic reforms
  • Lingmed innovative asset recommendation
  • The Feburary Financial analysis of global bio-pharmaceuticals market by Biotechgate data analysis team
Download the full report


Linkedbio Report No.160

Bio-Europe Spring 2018 - Lingmed asset recommendation

Company LMC5000479 is an emerging specialty pharmaceutical company focused on the development of therapeutics that improve the quality of women’s health. The Company’s well –recognized management team has pioneered market-leading products in fertility and female sexual health, having successfully developed, licensed and sold a few products. The company’s robust women’s health clinical development pipeline includes treatments for fertility menopausal hormone therapy, contraception and sexual health, in addition, the company’s male product has shown 81% success in a partially completed phase III study.
LMC5000479's lead product LMP1106 addresses a significant unmet medical and commercial need in Vaginal infections and Vaginitis, atrophic. LMP1106 is currently under phase III development, with the potential to enter the market in 2019.
Download the full report




If you are interested in Lingmed historical achieved reports, please click here





Confirm your details on form below to download this report

Company name *
Your name *
Email *
Phone *
Notes

©Copyright 2013 - 2018 Lingmed Limited